06 May, 2024 Will the PTO's Proposed Expansion of Filing Settlement Agreements Help to Reduce Drug Prices? By Chad Landmon Craig Minerva In a recent Federal Register notice, the PTO announced a proposed rule requiring that any settlement agreement resolving a PTAB...
22 Apr, 2024 Vanda Strikes Out at the Supreme Court By Chad Landmon Matt Murphy Thomas Hedemann Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable...
09 Apr, 2024 Vanda Swings for the Fences and Asks the Supreme Court to Heighten the Standard for Obviousness By Chad Landmon Matt Murphy Thomas Hedemann Among the most established standards in patent law is that obviousness requires a motivation to combine the prior art with “a reasonable...
25 Mar, 2024 More Lessons from Mumbai – Reflections on a Hatch-Waxman and PIV Litigation Panel Discussion By Chad Landmon Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I...
18 Mar, 2024 Going Global on Polymorphs By Ted Mathias Aziz Burgy Rebecca Clegg We were so pleased to have the opportunity to address InformaMarkets’ 13th Annual Pharma IPR Conference in Mumbai on legal challenges to...
11 Mar, 2024 Reconnecting in Mumbai at the 2024 Pharma IPR Conference By Chad Landmon Aziz Burgy Ted Mathias Rebecca Clegg +1 more... Show less We just returned from a weeklong trip to Mumbai in which Axinn served as the Platinum sponsor of InformaMarkets 13th Annual Pharma IPR...
16 Feb, 2024 Happy 40th Hatch-Waxman! By Chad Landmon Turning 40 is a big milestone for most of us. When I turned 40 – I won't tell you how long ago that was – I was knee-deep in Paragraph IV...
16 Feb, 2024 Pharma IPR Conference By Aziz Burgy Rebecca Clegg Chad Landmon Ted Mathias +1 more... Show less Axinn is proud to be a Platinum Partner of the Pharma IPR Conference On March 5 at 11:00 AM, partners Aziz Burgy, Ted Mathias, and...
14 Feb, 2024 Bayer Covenants Not to Sue, Still Has Headache By Ted Mathias Bayer's ‘053 patent on its drug Xarelto® expires in November 2024, and Bayer granted Mylan a covenant not to sue. Bayer has a second...
13 Feb, 2024 CREATing Controversy: Can a Brand Manufacturer Deny Sample Requests? By Chad Landmon Ian Swan Can a drug manufacturer refuse to provide samples of its innovator product under the CREATES Act if it thinks that the requester will not...
09 Feb, 2024 Will India Replace China in the U.S. Drug Supply Chain? By Chad Landmon In a recent opinion piece in Newsweek, Dr. Rahul Tiwari asserts that pharmaceutical companies in India have an opportunity to supplant...
29 Jan, 2024 Opening Another Front in the Brand/Generic Battle? By Chad Landmon Although it's not often that I read a decision by the U.S. Court of Federal Claims, it appears that Vanda may be opening a new front in...